Metabolic Syndrome: From the Pathophysiology to the Treatment. A Comprehensive Review

Author(s): Salvatore Novo, Bonomo Vito, Di Piazza Mariaconcetta, Piero Levantino

1. Avogaro P, Crepaldi G, Enzi G, Tiengo A: Associazione di iperlidemia, diabete mellito e obesità di medio grado. Acto Diabetol Lat 1967; 4: 36–41.
2. Haller H: Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med 1977; 32: 124–128.
3. Singer P: Diagnosis of primary hyperlipoproteinemias. Z Gesamte Inn Med 1977; 32: 129–133.
4. Himsworth H: Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 1: 127–130.
5. Shen S-W, Reaven GM, Farquhar JW: Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest 1970; 49: 2151–2160
6. Ginsburg H, Kimmerling G, Olefsky JM, Reaven GM: Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest ,1975; 55: 454–461
7. Reaven GM, Lerner R, Stern M, Farquhar JW: Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967; 46: 1756–1767
8. Olefsky JM, Farquhar JW, Reaven GM: Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551–560
9. Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL: Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 1983; 118: 326–337
10. Olefsky JM, Kolterman OG, Scarlett JA: Insulin action and resistance in obesity and non-insulin-dependent type II diabetes mellitus. Am J Physiol 1982; 243: E15–E30,
11. Stern MP, Haffner SM: Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986; 6: 123–130,
12. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z: Hyperinsulinemia: a link between hypertension, obesity, and glucose intolerance. J Clin Invest 1985; 75: 809–817
13. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK: Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 1988; 37: 338–345
14. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357
15. Wingard DL, Barrett-Connor E, Criqui MH, Suarez L: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 1983; 117: 19–26
16. Hanefeld M, Leonhardt W: Das Metabolische Syndrom. Dt Gesundh.-Wesen 1981; 36:545–551
17. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension,dyslipidemia, and atherosclerotic cardiovascular disease (Review). Diabetes Care 1991; 14:173–194
18. Descovich GC, Benassi B, Cancelli V, D’Addato S, De Simone, Dormi A: An epidemic view of the plurimetabolic syndrome. In Diabetes, Obesity and Hyperlipidemias. V. The Plurimetabolic Syndrome. Crepaleli G, Tiengo A, Manzato E, Eds. Amsterdam, Netherlands, Elsevier Science, 1993, p. 31–39
19. Bouchard C, Perusse L: Genetics of causes and manifestations of the metabolic syndrome. In Diabetes, obesity and hyperlipidemia: V. The plurimetabolic syndrome. Crepaldi G, Tiengo A, Manzato E, Eds., Amsterdam, Elsevier Science, 1993, p. 67–74
20. Kaplan NM: The deadly quartet: upperbody obesity, glucose intolerance, hypertriglyceridemia, and hypertension. ArchIntern Med 1989; 149:1514–1520
21. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva, World Health Org., 1999
22. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497
23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart, Lung, and Blood Institute, American Heart Association: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438
24. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B, European Group For The Study Of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364–376
25. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–252
26. Wilson PWF, Grundy SM: The metabolic syndrome: practical guide to origins and treatment: part I. Circulation 2003; 108: 1422–1425
27. Novo S, Balbarini A, Belch JJ, Bonura F, Clement DL, Diamantopoulos E, Fareed J, Norgren L, Poredos P, Rotzocil K; Guidelines Committee of the International Union of Angiology; Scientific Committee of the International Union of Angiology; Council of Vascular Medicine of the International Union of Angiology. The metabolic syndrome: definition, diagnosis and management. Int Angiol. 2008 Jun;27(3):220-31.
28. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640–1645.
29. Paul L. Huang, A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009 May-Jun; 2(5-6): 231–237.
30. Kim JA, Montagnani M, Koh KK, Quon MJ. Review Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006 Apr; 113(15):1888-904.
31. Pouliot MC, Després J-P, Nadeau A, Moorjani S, Prud’Homme D, Lupien PJ, Tremblay A, Bouchard C: Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826–834
32. Lemieux S, Tremblay A, Prud-Homme D, Bouchard C, Nadeau A, Després J-P: Seven-year changes in body fat and visceral adipose tissue in women: associations with indexes of plasma glucose-insulin homeostasis. Diabetes Care 1996; 19: 983–991
33. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE: Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997; 273: E425–E432
34. Fujimoto WY, Leonetti DL, Bergstrom RW, Newell-Morris L, Boyko EJ, Shofer JB, Chen K-W, Wahl PW: Visceral adiposity and incident coronary heart disease in Japanese-American men. Diabetes Care 1999; 22: 1808–1812
35. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE: Body composition, visceral fat, leptin and insulin resistance in Asian men. J Clin Endocrinol Metab 1999; 84: 137–144
36. Boyko EJ, Leonetti DL, Fujimoto WY, Newell-Morris L: Visceral adiposity and risk of type 2 diabetes. Diabetes Care 2000; 23: 465–471
37. Rendell M, Hulthen UL, Tornquist C, Groop L, Mattiasson I: Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001; 86: 744–749
38. Ross R, Freeman J, Hudson R, Janssen I: Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044–5051
39. Kershaw EE, Flier JS. Review Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun; 89(6):2548-56.
40. Semenkovich CF Review Insulin resistance and atherosclerosis. J Clin Invest. 2006 Jul; 116(7):1813-22.
41. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363–1379
42. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Review Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000 May; 902(2):230-240.
43. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994 Jan; 93(1):50-5.
44. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002 Apr 2; 105(13):1567-72.
45. Libby P, Ridker PM, Maseri A. Review Inflammation and atherosclerosis. Circulation. 2002 Mar 5; 105(9):1135-43.
46. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006; 55(10): 1293–1301.
47. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821.
48. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H: Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009; 32(9): 1737–1742.
49. Dehghan A, Van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008; 31(2): 361–362.
50. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42(3): 474–480.
51. So A, Thorens B: Uric acid transport and disease. J Clin Invest. 2010; 120(6): 1791–1799.
52. Kanellis J, Kang DH: Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephro.l 2005; 25(1): 39.42.
53. Li C, Hsieh MC, Chang SJ: Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013; 25(2): 210–216.
54. Facchini F, Chen YD, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc. 1991; 266(21): 3008–3011.
55. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciaciaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995; 268(1): E1–E5.
56. Muscelli E, Natali A, Bianchi S, Bigazzi S, Quinones Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996; 9(8): 746–752.
57. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011; 60(4): 1258–1269.
58. Gustafsson D, Unwin R: The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrology . 2013; 14: 164.
59. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, Levesque S, Varga S: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American J Cardiol. 2004; 93(2): 159–164. [PUBMED]
60. Kim JY, Mun HS, Lee BK, Yoon SB, Choi EY, Min PK, Yoon YW, Hong BK, Rim SJ, Kwon HM: Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. Yonsei Med J. 2010; 51(5): 676–682.
61. Yoon SE, Ahn SG, Kim JY, Park JS, Shin JH, Tahk SJ, Lee SK, Kim TJ, Han N: Differential relationship between metabolic syndrome score and severity of coronary atherosclerosis as assessed by angiography in a non-diabetic and diabetic Korean population. J Korean Med Sci. 2011; 26(7): 900–905.
62. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, Pacheco R, Bursac Z, Grant A, Mehta JL: Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. American J Cardiol. 2007; 99(7): 879–884.
63. Novo S, Peritore A, Guarneri FP, Corrado E, Macaione F, Evola S, Novo G. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis. 2012; 223: 468-472.
64. Novo S, Peritore A, Trovato RL, Guarneri FP, Di Lisi D, Muratori, Novo G. Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up. Cardiovascular Diabetology 2013, 12:155
65. Antonini-Canterin F1, La Carrubba S, Gullace G, Zito C, Di Bello V, Di Salvo G, Benedetto F, Novo S, Pezzano A, Perticone F, Balbarini A, Carerj S; Research Group of the Italian Society of Cardiovascular Echography. Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study. Angiology. 2010 Jul;61(5):443-8.
66. Hunt KJ, Resendez, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–1257
67. Scuteri A, Najjar S, Morrell C, Lakatta E: The metabolic syncrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care 2005; 28: 882–887
68. Novo G, Corrado E, Muratori I, Tantillo R, Bellia A, Galluzzo A, Vitale G, Novo S. Markers of inflammation and prevalence of vascular disease in patients with metabolic syndrome.Int Angiol. 2007 Dec;26(4):312-7.
69. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron Artery Dis. 2009 Jan;20(1):15-20.
70. Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. 2006 Jan 4;106(1):16-20.
71. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010 Feb;17(1):1-11.
72. Corrado E, Novo S. Evaluation of C-reactive protein in primary and secondary prevention. J Investig Med. 2007 Dec;55(8):430-8.
73. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818–2825
74. Corrado E, Rizzo M, Aluigi L, Patti AM, Coppola G, Muratori I, Caccamo G, Balasus F, Novo S. Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. Int Angiol. 2012 Jun;31(3):219-26.
75. Corrado E, Rizzo M, Caccamo G, Coppola G, Muratori I, Tantillo R Dell'oglio S, Nugara C, Macaione F, Novo G, Alcamo R, Mignano A, Ferrara F, Novo S. Prevalence of metabolic syndrome: a comparative analysis in an unselected sample of mediterranean subjects. Int Angiol. 2012 Dec; 31(6): 572-8.
76. Esposito K, Ciotola M, Giugliano D. Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res. 2007 Oct;51(10):1268-74.
77. Fappa E, Yannakoulia M, Pitsavos C, et al. Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues?. Nutrition. 2008 Mar;24(3):286-91.
78. Bateman LA, Slentz CA, Willis LH, et al. Comparison of Aerobic Versus Resistance Exercise Training Effects on Metabolic Syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise - STRRIDE-AT/RT). Am J Cardiol. Sep 15 2011;108(6):838-44.
79. Shuval K, Finley CE, Chartier KG, Balasubramanian BA, Gabriel KP, Barlow CE. Cardiorespiratory Fitness, Alcohol Intake, and Metabolic Syndrome Incidence in Men. Med Sci Sports Exerc. 2012 Nov;44(11):2125-31.
80. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.
81. Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06030-0.
82. Jensen MD, Ryan DH, Apovian CM, Loria CM, Ard JD, Millen BE. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013 Nov 7. pii: S0735-1097(13)06030-0.
83. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013 Aug 13;62(7):569-76.
84. Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med. Dec 15 2011;365(24):2277-86
85. Chan DC, Watts GF, Barrett PH, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002 Aug;51(8):2377-86
86. Catapano AL, Averna M, Faggiano P, Novo S. The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias. G Ital Cardiol (Rome). 2014 Jan;15(1):19-20.
87. Sucato V, Triolo OF, Bronte E, Trovato RL, Tona GR, Novo S. Dyslipidemia management with medical nutrition therapy: current status and perspectives. Recenti Prog Med. 2013 Sep;104(9):476-81.
88. Fazio G, Amoroso GR, Barbaro G, Novo G, Novo S. The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome. Curr Pharm Des. 2008;14(25):2605-12.
89. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 Apr;142(8):611-9.
90. Nieuwdorp M, Stroes ES, Kastelein JJ. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab. 2007 Nov;9(6):869-78.
91. Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007 Feb;37(2):79-86.
92. Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav. 2008 May;94(2):187-97.
93. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009 Jan;53(3):298-304.
94. Shields TM, Hennekens CH. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin North Am. 2004 Sep;33(3):577-93, vii.
95. Blaha MJ, Bansal S, Rouf R, et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin Proc. 2008 Aug;83(8):932-41.
96. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the proinflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33:431–453.
97. Tupper T, Gopalakrishnan G. Prevention of diabetes development in those with the metabolic syndrome. Med Clin North Am. 2007 Nov;91(6):1091-105